Valeant Pharmaceuticals Intl Inc (VRX) Price Target Cut to C$18.00
Valeant Pharmaceuticals Intl Inc (TSE:VRX) had its price objective dropped by analysts at TD Securities from C$38.50 to C$18.00 in a research note issued on Thursday. The brokerage presently has a “hold” rating on the specialty pharmaceutical company’s stock. TD Securities’ price objective would suggest a potential downside of 26.29% from the stock’s current price.
Several other research firms also recently issued reports on VRX. Royal Bank Of Canada reiterated a “sector perform” rating and set a C$46.50 price objective on shares of Valeant Pharmaceuticals Intl in a research note on Tuesday, August 23rd. Scotiabank decreased their price objective on shares of Valeant Pharmaceuticals Intl from C$35.00 to C$32.00 and set a “sector perform” rating for the company in a research note on Monday, July 25th.
Shares of Valeant Pharmaceuticals Intl (TSE:VRX) opened at 24.42 on Thursday. The firm’s market capitalization is $8.49 billion. The company’s 50-day moving average is $29.16 and its 200 day moving average is $32.91. Valeant Pharmaceuticals Intl has a 52 week low of $18.41 and a 52 week high of $165.77.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Stock Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related stocks with our FREE daily email newsletter.